Added Value of QuantiFERON TB-Gold in-Tube for Detecting Latent Tuberculosis Infection among Persons Living with HIV/AIDS
Added Value of QuantiFERON TB-Gold in-Tube for Detecting Latent Tuberculosis Infection among Persons Living with HIV/AIDS
dc.contributor.author | Souza, Josiane Maria Oliveira | |
dc.contributor.author | Evangelista, Maria do Socorro Nantua | |
dc.contributor.author | Trajman, Anete | |
dc.date.accessioned | 2025-01-03T14:43:20Z | |
dc.date.available | 2025-01-03T14:43:20Z | |
dc.date.issued | 2014 | |
dc.description.abstract | Objective. To evaluate the added value of QuantiFERON TB-Gold in-Tube (QTF-GIT) over the tuberculin skin testing (TST) for detecting latent tuberculosis (TB) infection (LTBI) among patients with AIDS in a city with a low TB incidence rate (11.1/100,000 inhabitants) and universal BCG coverage. Methods. Three hundred consecutive patients with AIDS in eight outpatient sexually transmitted disease public clinics in Brasilia were submitted to QFT-IT and TST between May 2011 and March 2013. A positive result of either test was considered to be LTBI. Results. Median CD4-cell count was 477.5 cells/mm3 ; 295 (98.3%) were using antiretroviral therapy. Eighteen patients (6%, 95% CI: 3.6%–9.3%) had LTBI, of whom 4 (1.3%, 95% CI: 0.04%–2.63%) had only a positive TST, 8 (2.7%, 95% CI: 0.8%–4.5%) had only a QFT-GIT positive test, and 6 (2%, 95% CI: 0.4%–3.6%) had positive results for both tests. This represents an 81.8% relative increase in LTBI detection when QFT-GIT is added to TST. The concordance between both tests was 96% (k = 0.48). Conclusions. The QFT-GIT alone was more effective to detect LTBI than TST alone and had an 81% added value as an add-on sequential test in this population with mild immunosuppression. The cost-effectiveness of these strategies remains to be evaluated. | |
dc.identifier.citation | Souza JM, Evangelista Mdo S, Trajman A. Added value of QuantiFERON TB-gold in-tube for detecting latent tuberculosis infection among persons living with HIV/AIDS. Biomed Res Int. 2014;2014:294963. doi: 10.1155/2014/294963. Epub 2014 May 29. | |
dc.identifier.other | DOI: 10.1155/2014/294963 | |
dc.identifier.uri | https://dspace.inc.saude.gov.br/handle/123456789/735 | |
dc.language.iso | en | |
dc.publisher | BioMed Research International | |
dc.subject | Acquired Immunodeficiency Syndrome / complications | en |
dc.subject | Acquired Immunodeficiency Syndrome / microbiology | en |
dc.subject | Acquired Immunodeficiency Syndrome / pathology* | en |
dc.subject | Adult | en |
dc.subject | CD4 Lymphocyte Count | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Interferon-gamma Release Tests | |
dc.subject | Latent Tuberculosis / complications | |
dc.subject | Latent Tuberculosis / diagnosis* | |
dc.subject | Latent Tuberculosis / pathology* | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Tuberculin Test / methods* | |
dc.title | Added Value of QuantiFERON TB-Gold in-Tube for Detecting Latent Tuberculosis Infection among Persons Living with HIV/AIDS | |
dc.type | Article |